BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...ElsaLys Biotech S.A.S., Lyon, France Empirica Therapeutics Inc., Hamilton, Canada Genkyotex S.A. (Euronext:GKTX), Saint-Julien-en-Genevois, France HEC Pharm Group...
BioCentury | Mar 20, 2018
Distillery Therapeutics

Neurology

...has the small molecule FLT3 inhibitor FF-10101 (FF-10101-01) in Phase I/II testing to treat AML. HEC Pharm Group...
BioCentury | Jan 15, 2018
Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

...development since then -- anti-Axl kinase mAb BGB149 from BerGenBio ASA (OSE:BGBIO) and CT413 from HEC Pharm Group...
BioCentury | Oct 10, 2017
Distillery Therapeutics

Cancer

...FLT3, in Phase I/II testing; Fujifilm Holdings Corp. has FF-10101 in Phase I/II testing; and HEC Pharm Group...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Cancer

...in Phase I/II testing; Fujifilm Holdings Corp. has FF-10101 in Phase I testing ; and HEC Pharm Group...
BioCentury | Nov 11, 2016
Company News

HEC, TaiGen deal

...month. HEC Pharm Group , Dongguan, China TaiGen Biopharmaceuticals Holdings Ltd. (TPex:4157), Taipei, Taiwan Business: Infectious Nora Weintraub DAG-181 NS5A inhibitor TG-2349 HEC Pharm Group TaiGen...
BioCentury | Oct 31, 2016
Company News

TaiGen, HEC launch cross-strait newco for HCV combo

...Biopharmaceuticals Holdings Ltd. (TPex:4157) and the YiChang HEC ChangJiang Pharmaceutical Co. Ltd. (HKSE:1558) subsidiary of HEC Pharm Group...
Items per page:
1 - 7 of 7
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...ElsaLys Biotech S.A.S., Lyon, France Empirica Therapeutics Inc., Hamilton, Canada Genkyotex S.A. (Euronext:GKTX), Saint-Julien-en-Genevois, France HEC Pharm Group...
BioCentury | Mar 20, 2018
Distillery Therapeutics

Neurology

...has the small molecule FLT3 inhibitor FF-10101 (FF-10101-01) in Phase I/II testing to treat AML. HEC Pharm Group...
BioCentury | Jan 15, 2018
Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

...development since then -- anti-Axl kinase mAb BGB149 from BerGenBio ASA (OSE:BGBIO) and CT413 from HEC Pharm Group...
BioCentury | Oct 10, 2017
Distillery Therapeutics

Cancer

...FLT3, in Phase I/II testing; Fujifilm Holdings Corp. has FF-10101 in Phase I/II testing; and HEC Pharm Group...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Cancer

...in Phase I/II testing; Fujifilm Holdings Corp. has FF-10101 in Phase I testing ; and HEC Pharm Group...
BioCentury | Nov 11, 2016
Company News

HEC, TaiGen deal

...month. HEC Pharm Group , Dongguan, China TaiGen Biopharmaceuticals Holdings Ltd. (TPex:4157), Taipei, Taiwan Business: Infectious Nora Weintraub DAG-181 NS5A inhibitor TG-2349 HEC Pharm Group TaiGen...
BioCentury | Oct 31, 2016
Company News

TaiGen, HEC launch cross-strait newco for HCV combo

...Biopharmaceuticals Holdings Ltd. (TPex:4157) and the YiChang HEC ChangJiang Pharmaceutical Co. Ltd. (HKSE:1558) subsidiary of HEC Pharm Group...
Items per page:
1 - 7 of 7